Rectal adenocarcinoma. Malignant neoplasm of rectum
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will first receive neoadjuvant treatment via pelvic radiotherapy with capecitabine tablets, then neoadjuvant chemotherapy with FOLFOX or CapO
Sponsors
Mashhad University of Medical Sciences
Sabzevar University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with rectal adenocarcinoma based on pathological diagnosis The zero to two level of Eastern Cooperative Oncology Group (ECOG) Healthy functioning bone marrow Healthy functioning liver Healthy functioning kidneys
Exclusion criteria
Exclusion criteria: Having simultaneous adenocarcinoma in other areas of the colon Having metastasis History of previous malignancy History of chemotherapy History of pelvic radiotherapy Having inflammatory intestinal disease Having bilateral hip prosthesis Having allergic to 5-fluorouracil and its other derivatives Having allergic to oxaliplatin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The pathological complete response. Timepoint: One week after surgery. Method of measurement: Based on surgical pathology report.;Local recurrence. Timepoint: One year after intervention. Method of measurement: Pelvic computed tomography (CT) scan and colonoscopy.;Distant metastasis. Timepoint: One year after intervention. Method of measurement: Abdominal and pelvic CT scan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications of treatment. Timepoint: One, two and three weeks after treatment. Method of measurement: Based on the Common Terminology Criteria for Adverse Events (CTCAE). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFereshteh Foroughi Pordanjani
Mashhad University of Medical Sciences
Outcome results
None listed